Healthcares was Foxo Technologies’s largest segment in fiscal 2025, bringing in $48.26M of $49.10M (98%).
| Segment | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Healthcares | — | — | $12.06M | $48.26M |
| Other Operating | $1.45M | — | — | — |
| Life Science Services | — | — | — | $757.51K |
| Labs & Life | — | $435.87K | — | — |
| Labs | — | — | $97.92K | $41.77K |
| Corporate Segment & Other Operating | — | — | — | $45.28K |
| Total | $1.45M | $435.87K | $12.15M | $49.10M |
Foxo Technologies brought in $49.10M from its four segments in fiscal 2025, the year ended December 31, 2025. Foxo Technologies regrouped these segments after fiscal 2024, so the total does not compare directly with that year's $12.15M. Healthcares was the largest at $48.26M (98.3%), ahead of Life Science Services at $757.51K (1.5%) and Corporate Segment & Other Operating at $45.28K (0.1%). The remaining segment, Labs, brought in $41.77K.
Foxo Technologies began breaking out Healthcares in fiscal 2024, Life Science Services in fiscal 2025, Labs in fiscal 2024 and Corporate Segment & Other Operating in fiscal 2025. Foxo Technologies stopped reporting Other Operating ($1.45M in fiscal 2022) and Labs & Life ($435.87K in fiscal 2023) as separate segments.
Epigenetic Biomarker Services was Foxo Technologies’s largest product and service line in fiscal 2022, bringing in $1.20M of $1.53M (78%).
| Product and Service | FY 2022 |
|---|---|
| Epigenetic Biomarker Services | $1.20M |
| Epigenetic Biomarker Royalties | $249.00K |
| Life Insurance Commissions | $84.00K |
| Total | $1.53M |
Foxo Technologies brought in $1.53M from its three product and service lines in fiscal 2022, the year ended December 31, 2022. Epigenetic Biomarker Services was the largest at $1.20M (78.3%), ahead of Epigenetic Biomarker Royalties at $249.00K (16.2%) and Life Insurance Commissions at $84.00K (5.5%).
Foxo Labs was Foxo Technologies’s largest revenue line in fiscal 2022, bringing in $1.45M of $1.53M (95%).
| Title Of Individual | FY 2022 |
|---|---|
| Foxo Labs | $1.45M |
| Foxo Life | $84.00K |
| Total | $1.53M |
Foxo Technologies brought in $1.53M from its two revenue lines in fiscal 2022, the year ended December 31, 2022. Foxo Labs was the largest at $1.45M (94.5%), ahead of Foxo Life at $84.00K (5.5%).
Foxo Technologies (FOXO) reports its revenue by segment, by product and service and by title of individual. In fiscal 2025, Healthcares was its largest segment, bringing in $48.26M (98.3% of the total), followed by Life Science Services at $757.51K (1.5%).
Healthcares was Foxo Technologies' largest segment in fiscal 2025, bringing in $48.26M, or 98.3% of the $49.10M total across its four segments.
Epigenetic Biomarker Services was Foxo Technologies' largest product and service line in fiscal 2022, bringing in $1.20M, or 78.3% of the $1.53M total across its three product and service lines.
Foxo Labs was Foxo Technologies' largest revenue line in fiscal 2022, bringing in $1.45M, or 94.5% of the $1.53M total across its two revenue lines.
Every figure comes from Foxo Technologies' annual financial filings, as reported. Each line keeps the name Foxo Technologies gives it, and years follow its fiscal calendar.
Foxo Technologies' revenue by segment goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.